Significantly higher polybrominated diphenyl ether levels in young U.S. children than in their mothers

Sonya Lunder1, Lotta Hovander, Ioannis Athanassiadis

  • 1Environmental Working Group, Washington, DC 20009, USA.

Insights

Young children have significantly higher polybrominated diphenyl ether (PBDE) levels than their mothers, indicating increased exposure risks. This highlights the need for targeted biomonitoring in pediatric populations for environmental contaminants.

Area of Science:

  • Environmental Health
  • Toxicology
  • Pediatric Health

Background:

  • Polybrominated diphenyl ethers (PBDEs) are common flame retardants found in indoor environments.
  • PBDEs are detected at higher levels in Americans compared to other populations.
  • Limited research exists on PBDE exposure in U.S. children, who may be at higher risk due to ingestion of contaminants.

Purpose of the Study:

  • To investigate and compare polybrominated diphenyl ether (PBDE) concentrations in young children and their mothers.
  • To test the hypothesis that PBDE levels are higher in children than in their mothers.

Main Methods:

  • Blood samples were collected concurrently from 20 mother-child pairs (children aged 1.5 to 4 years).
  • Gas chromatography/mass spectrometry (GC/MS) with selected ion monitoring was used for chemical analysis.
  • Quantification of 20 PBDE congeners, with 11 detected in the samples.

Main Results:

  • Children exhibited significantly higher total PBDE (SigmaPBDE) concentrations, averaging 2.8 times higher than their mothers.
  • Median child-to-mother ratios for individual congeners ranged from 2 to 4.
  • Nineteen out of twenty families showed higher PBDE levels in children, with statistically significant differences for five congeners.

Conclusions:

  • Young children accumulate higher levels of PBDEs than their mothers, suggesting intense early-life exposure.
  • Factors such as hand-to-mouth behavior, diet, and potential breast milk transfer contribute to children's higher exposure.
  • Adult biomonitoring data may not accurately represent exposure levels in young children residing in the same environment.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...